Archive for: drug pricing

  • ORIGINAL ANALYSIS

  • PDF DOWNLOAD

  • EXTERNAL LINK

  • POST

Prescription Drug: Original Analysis

Prescription Drug Pricing Tracker

There are a lot of moving parts when it comes to prescription drug cost reform. Keep up-to-date with our tracker! (Updated 11.18.19)

POST

Payment Innovation: Other

MedPAC Continues Work on Part D Redesign, Unified PAC Payment System and Discusses Population-based Outcome Measures

MedPAC met in Washington, DC on October 3-4, 2019 and the Commission continued the discussion on a variety of innovation topics.

POST

Prescription Drug: Legislation

Summary of Senate Finance Prescription Drug Package

Senate Finance Committee posts description of the Chairman’s mark of its legislation addressing prescription drug pricing.

POST

Prescription Drug: Pricing

Administration Withdraws Rebate Overhaul Proposal

The Administration has announced it is no longer pursuing its drug pricing proposal that would have required pharmacy benefit managers to pass rebates directly on to the patient.

POST

Prescription Drug: Litigation

Judge Axes Price Disclosure Rule for Drug Ads

  The Trump administration cannot force drug manufacturers to disclose prices in their pharmaceutical ads to consumers, a federal judge ruled Monday.  

EXTERNAL LINK

Prescription Drug: Legislation

Prescription Drug Legislation Considered

House E&C Health Subcommittee holds legislative hearing to examine seven bills related to lowering the cost of prescription drugs.

POST

Prescription Drug: Legislation

Accelerated Drug Approval for Prescription Therapies (ADAPT) Act

On March 6, 2019, Senator Mike Braun (R-IN) introduced the Accelerated Drug Approval for Prescription Therapies (ADAPT) Act (S. 658), which would create an expedited drug approval process at FDA specifically for drugs that are currently approved for sale in developed countries.

EXTERNAL LINK

Prescription Drug: Legislation

Drug Price Transparency (DPT) Act

On March 6, 2019, Senator Mike Braun (R-IN) introduced the Drug Price Transparency (DPT) Act (S. 657), which would extend the idea of the HHS OIG PBM rebate rule to the commercial insurance market and prohibit PBMs from receiving any rebates or reductions in price from drug manufacturers.

EXTERNAL LINK

Payment Innovation: Other

CMS Approves Drug Price Negotiations for Colorado Medicaid

Colorado has become the latest state to receive approval from CMS for negotiating drug prices for Medicaid recipients using value-based contracting arrangements.

POST

Payment Innovation: Other

Senators Cassidy and Warner Introduce PAVE Act

Senators Cassidy and Warner Introduce Patient Affordability, Value and Efficiency (PAVE) Act.

POST

Load more
beakernav X1E2BFA62-BFCE-43C1-B777-27E3E5216018medical bagoriginal analysis +external linkpdf downloadstethoscope